CR and CRi of 80% and 100%, were also achieved in NPM1-mutated AML patients, when venetoclax was combined with 5 + 2 (cytarabine + idarubicin) or FLAG + IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) (ACTRN12616000445471, NCT03214562) [79, 80]. This evidence concerns the gene NPM1 and acute myeloid leukemia.